Cargando…

Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer

BACKGROUND: Dual inhibition of PI3K and MAPK signaling is conceptually a promising anticancer therapy. OBJECTIVE: This phase 1b trial investigated the safety, maximum tolerated dose (MTD), recommended phase II dose, pharmacokinetics, tumor response, fluorodeoxyglucose positron emission tomography (F...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ramanathan, Ramesh K., Von Hoff, Daniel D., Eskens, Ferry, Blumenschein, George, Richards, Donald, Genvresse, Isabelle, Reschke, Susanne, Granvil, Camille, Skubala, Adam, Peña, Carol, Mross, Klaus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7591420/ https://www.ncbi.nlm.nih.gov/pubmed/32314268 http://dx.doi.org/10.1007/s11523-020-00714-0

Ejemplares similares

Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer
por: Ramanathan, Ramesh K., et al.
Publicado: (2020)

Pharmacokinetics of intravenous pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor [(14)C]copanlisib (BAY 80-6946) in a mass balance study in healthy male volunteers
por: Gerisch, Michael, et al.
Publicado: (2017)

A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib
por: O’Shea, John, et al.
Publicado: (2017)

MEK1/2 Inhibition in Murine Heart and Aorta After Oral Administration of Refametinib Supplemented Drinking Water
por: Steijns, Felke, et al.
Publicado: (2020)

Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer
por: Kim, R D, et al.
Publicado: (2018)

First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas
por: Patnaik, A., et al.
Publicado: (2016)

Allosteric Kinase Inhibitors Reshape MEK1 Kinase Activity Conformations in Cells and In Silico
por: Fleischmann, Jakob, et al.
Publicado: (2021)

The PI3K inhibitor copanlisib synergizes with sorafenib to induce cell death in hepatocellular carcinoma
por: Ye, Liangtao, et al.
Publicado: (2019)

Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer “PantHER”
por: Keegan, Niamh M., et al.
Publicado: (2021)

Update on the role of copanlisib in hematologic malignancies
por: Le, Thuy, et al.
Publicado: (2021)

Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells
por: Okabe, Seiichi, et al.
Publicado: (2016)

Safety and antitumor activity of copanlisib in Japanese patients with relapsed/refractory indolent non-Hodgkin lymphoma: a phase Ib/II study
por: Fukuhara, Noriko, et al.
Publicado: (2022)

Substituted 3-Benzylcoumarins as Allosteric MEK1 Inhibitors: Design, Synthesis and Biological Evaluation as Antiviral Agents
por: Wang, Chao, et al.
Publicado: (2013)

Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma
por: Dreyling, M., et al.
Publicado: (2017)

Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib
por: Krause, Günter, et al.
Publicado: (2018)

Insights into the binding mode of MEK type-III inhibitors. A step towards discovering and designing allosteric kinase inhibitors across the human kinome
por: Zhao, Zheng, et al.
Publicado: (2017)

Towards new treatment options for renal cell carcinoma: development and clinical results of tivozanib, a selective VEGFR tyrosine kinase inhibitor
por: Eskens, Ferry ALM, et al.
Publicado: (2012)

Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3‐Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations
por: Bardia, Aditya, et al.
Publicado: (2019)

A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2016)

Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma
por: Matasar, Matthew J., et al.
Publicado: (2021)

Validated HPLC method for quantification of copanlisib in mice plasma: application to a pharmacokinetic study
por: Zakkula, Ashok, et al.
Publicado: (2020)

A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours
por: Schram, Alison M., et al.
Publicado: (2018)

Ligand Docking Methods to Recognize Allosteric Inhibitors for G-Protein-Coupled Receptors
por: Harini, K, et al.
Publicado: (2021)

Copanlisib for the Treatment of Malignant Lymphoma: Clinical Experience and Future Perspectives
por: Munoz, Javier, et al.
Publicado: (2021)

MEK and the inhibitors: from bench to bedside
por: Akinleye, Akintunde, et al.
Publicado: (2013)

Current Development Status of MEK Inhibitors
por: Cheng, Ying, et al.
Publicado: (2017)

Model‐informed approach to support pediatric dosing for the pan‐PI3K inhibitor copanlisib in children and adolescents with relapsed/refractory solid tumors
por: Morcos, Peter N., et al.
Publicado: (2023)

Copanlisib in the Treatment of Relapsed Follicular Lymphoma: Utility and Experience from the Clinic
por: Chauhan, Ayushi F, et al.
Publicado: (2021)

Allosteric Inhibitors of NMDA Receptor Functions
por: Popescu, Gabriela K., et al.
Publicado: (2010)

Small Molecule Allosteric Inhibitors of BAX
por: Garner, Thomas P., et al.
Publicado: (2019)

Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results
por: Kefford, Richard, et al.
Publicado: (2014)

Discovery and SAR of Novel 2,3‐Dihydroimidazo[1,2‐c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80‐6946)
por: Scott, William J., et al.
Publicado: (2016)

MEK inhibitors for the treatment of NRAS mutant melanoma
por: Sarkisian, Saro, et al.
Publicado: (2018)

Experimental treatment of NRAS-mutated neurocutaneous melanocytosis with MEK162, a MEK-inhibitor
por: Küsters-Vandevelde, Heidi VN, et al.
Publicado: (2014)

Histone deacetylase inhibitors: a promising partner for MEK inhibitors in uveal melanoma?
por: Faião-Flores, Fernanda, et al.
Publicado: (2019)

Diarrhea and colitis related to immune checkpoint inhibitor and BRAF/MEK inhibitor therapy
por: Kuang, Andrew G., et al.
Publicado: (2023)

Expanding the Diversity of Allosteric Bcr-Abl Inhibitors
por: Deng, Xianming, et al.
Publicado: (2010)

Inhibitors of BRAF dimers using an allosteric site
por: Cotto-Rios, Xiomaris M., et al.
Publicado: (2020)

Inhibitors in AKTion: ATP-competitive vs allosteric
por: Lazaro, Glorianne, et al.
Publicado: (2020)

Mechanisms of allosteric and mixed mode aromatase inhibitors
por: Souza, Samson A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_39g3d98ktg5mq2qkt84cg6u395